Editorial: Right-First-Time Innovation Approach Drives Continual Investment

PharmasAlmanac_Q4.pngAs published in Pharma's Almanac Q4 2017.

Efficient development of optimal routes and manufacturing processes for the production of increasingly complex small molecule APIs requires extensive expertise, advanced equipment and technology, and a right-first-time mentality. Demonstration of these capabilities has resulted in growing demand and a need for continual investment at Alcami’s Germantown, Wisconsin facility.

Despite much discussion of the growing importance of biologics in the pharmaceutical industry pipeline, small molecule drugs still account for the greatest percentage of drug sales and make up the greatest percentage of drugs in development today.¹ ² As a result, the global small molecule active pharmaceutical ingredient (API) market is expanding at a rate of approximately 7.0% per year from 2016 to 2027 to reach a value of $279.7 billion, according to Cooked Research Reports.³

 Download Full Article 

Topics: Thought Leadership Editorials